Nanexa ABFRA:40M +2.02%48 PS Ratio is 15.92 as of Jul. 08, 2026, which is 77% below its 10-year median of 69.90. GuruFocus rates FRA:40M with a GF Score™ of 48/100 and a GF Value™ of €0.17 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 952 Drug Manufacturers companies, Nanexa AB ranks worse than 92.12% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Nanexa AB's share price is €0.3025.
Nanexa AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.02. Hence, Nanexa AB's PS Ratio for today is 15.92.
Good Sign:
Nanexa AB stock PS Ratio (=16.44) is close to 1-year low of 15.09.
The historical rank and industry rank for Nanexa AB's PS Ratio or its related term are showing as below:
FRA:40M'
s PS Ratio Range Over the Past 10 Years
Min: 1.73 Med: 69.9 Max: 617.28
Current: 15.8
During the past 12 years, Nanexa AB's highest PS Ratio was 617.28. The lowest was 1.73. And the median was 69.90.
FRA:40M's PS Ratio is ranked worse than 92.12% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs FRA:40M: 15.80
During the past 12 months, the average Revenue per Share Growth Rate of Nanexa AB was 57.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 55.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 28.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 20.80% per year.
During the past 12 years, Nanexa AB's highest 3-Year average Revenue per Share Growth Rate was 126.10% per year. The lowest was -39.60% per year. And the median was 42.85% per year.
Back to Basics: PS Ratio
Nanexa AB (FRA:40M) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Nanexa AB PS Ratio Related Terms
Nanexa AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Nanexa AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanexa AB PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Nanexa AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Nanexa AB's Share Price of today is €0.3025. Nanexa AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Nanexa AB (FRA:40M) has a PS Ratio of 15.92 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nanexa AB and its competitors. This is 77% below median its historical median of 69.90. Over the past decade, Nanexa AB's PS Ratio has ranged from 1.73 to 617.28. According to the industry distribution chart, Nanexa AB ranks #877 out of 952 companies in the Drug Manufacturers industry, placing it in the top 92.1%.
Is Nanexa AB's PS Ratio too high?
Nanexa AB's current PS Ratio of 15.92 is 77% below median its 10-year median of 69.90. Over the past 10 years, this metric has ranged from a low of 1.73 to a high of 617.28. The Drug Manufacturers industry median PS Ratio is 2.29. Nanexa AB's value of 15.92 is 595.2% above this industry median. Based on the distribution chart, Nanexa AB ranks #877 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nanexa AB has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanexa AB's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nanexa AB ranks #877 out of 952 companies for PS Ratio. This places Nanexa AB in the lower half of its industry. The industry median PS Ratio is 2.29. Nanexa AB's value of 15.92 is 595.2% above this benchmark. Historically, Nanexa AB's own PS Ratio has ranged from 1.73 to 617.28 over the past decade. While the company's 10-year median is 69.90 vs. the industry median of 2.29, Nanexa AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.29, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanexa AB's current PS Ratio of 15.92 is 595.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nanexa AB and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanexa AB's current PS Ratio is 15.92, which is 77% below median its own 10-year median of 69.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanexa AB stock overvalued right now?
Based on GuruFocus' analysis, Nanexa AB (FRA:40M) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €0.30 — trading 77.9% above its estimated fair value. The current PS Ratio is 15.92, which is 77% below median its 10-year median of 69.90 and 595.2% above the Drug Manufacturers industry median of 2.29. Nanexa AB's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Nanexa AB (FRA:40M), the current PS Ratio is 15.92 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanexa AB (FRA:40M) Overvalued in 2026?
Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued.
The current stock price of €0.30 is trading 77.9% above its estimated GF Value™ of €0.17.
GuruFocus considers Nanexa AB to be Significantly Overvalued.
Key valuation signals for FRA:40M:
PS Ratio: 15.92 (77% below median its 10-year median of 69.90)
GF Value™: €0.17 vs. price of €0.30 (77.9% above fair value)
Industry Position: 595.2% above the Drug Manufacturers median (#877 of 952)
No single metric tells the full story. See the FRA:40M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
48GF Score
Get the complete analysis for FRA:40M
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:40M has been successfully added to your 
